Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 16:9:F1000 Faculty Rev-1146.
doi: 10.12688/f1000research.26841.1. eCollection 2020.

New and Emerging Therapies in the Management of Bladder Cancer

Chelsea K Osterman  1 , Matthew I Milowsky  1   2
Affiliations
Review

New and Emerging Therapies in the Management of Bladder Cancer

Chelsea K Osterman et al. F1000Res. .

Abstract

The treatment landscape for bladder cancer has undergone a rapid evolution in the past five years with the approval of seven new agents. New classes of medications have improved outcomes for many patients who previously had limited treatment options, but there is still much to learn about how to optimize patient selection for these agents and the role of combination therapies. The aims of this review are to discuss these newly approved agents for bladder cancer and to feature promising drugs and combinations-including immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates-that are in development.

Keywords: antibody-drug conjugate; immunotherapy; metastatic; muscle-invasive bladder cancer; targeted therapy; urothelial carcinoma.

PubMed Disclaimer

Conflict of interest statement

Competing interests: CKO declares that she has no competing interests. MIM reports research funding to his institution from Merck, Acerta Pharma, Roche/Genentech, Bristol-Myers Squibb, Seattle Genetics, Incyte, Astellas Pharma, Clovis Oncology, Inovio Pharmaceuticals, AstraZeneca, X4 Pharmaceuticals, Mirati Therapeutics, Boehringer Ingelheim, Constellation Pharmaceuticals, Jounce Therapeutics, Syndax, Innocrin Pharma, MedImmune, and Cerulean Pharma and consulting fees to his institution from Asieris. (See also https://coi.asco.org/share/7UQ-6ARQ/Matthew%20Milowsky.)No competing interests were disclosed.No competing interests were disclosed.

References

    1. National Cancer Institute: SEER Cancer Stat Facts: Bladder Cancer. Accessed August 31, 2019. Reference Source
    1. van Rhijn BWG, Burger M, Lotan Y, et al. : Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430–42. 10.1016/j.eururo.2009.06.028 - DOI - PubMed
    1. von der Maase H, Hansen SW, Roberts JT, et al. : Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77. 10.1200/JCO.2000.18.17.3068 - DOI - PubMed
    1. Patel MR, Ellerton J, Infante JR, et al. : Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018;19(1):51–64. 10.1016/S1470-2045(17)30900-2 - DOI - PMC - PubMed
    1. Powles T, O'Donnell PH, Massard C, et al. : Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol. 2017;3(9):e172411. 10.1001/jamaoncol.2017.2411 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances